Clinical utility of risk modelsto refer patients with adnexal masses to specialized oncology care: Multicenter external validation using decision curve analysis

Antonia Carla Testa, Laure Wynants, Dirk Timmerman, Jan Y. Verbakel, Luca Savelli, Daniela Fischerova, Dorella Franchi, Caroline Van Holsbeke, Elisabeth Epstein, Wouter Froyman, Stefano Guerriero, Alberto Rossi, Robert Fruscio, Francesco P.G. Leone, Tom Bourne, Lil Valentin, Ben Van Calster

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)

Abstract

Purpose: To evaluate the utility of preoperative diagnostic models for ovarian cancer based on ultrasound and/or biomarkers for referring patients to specialized oncology care. The investigated models were RMI, ROMA, and 3 models from the International Ovarian Tumor Analysis (IOTA) group [LR2, ADNEX, and the Simple Rules risk score (SRRisk)]. Experimental Design: A secondary analysis of prospectively collected data from 2 cross-sectional cohort studies was performed to externally validate diagnostic models. A total of 2, 763 patients (2, 403 in dataset 1 and 360 in dataset 2) from 18 centers (11 oncology centers and 7 nononcology hospitals) in 6 countries participated. Excised tissue was histologically classified as benign or malignant. The clinical utility of the preoperative diagnostic models was assessed with net benefit (NB) at a range of risk thresholds (5%-50% risk of malignancy) to refer patients to specialized oncology care. We visualized results with decision curves and generated bootstrap confidence intervals. Results: The prevalence of malignancy was 41% in dataset 1 and 40% in dataset 2. For thresholds up to 10% to 15%, RMI and ROMA had a lower NB than referring all patients. SRRisks and ADNEX demonstrated the highest NB. At a threshold of 20%, the NBs of ADNEX, SRrisks, and RMI were 0.348, 0.350, and 0.270, respectively. Results by menopausal status and type of center (oncology vs. nononcology) were similar. Conclusions: All tested IOTA methods, especially ADNEX and SRRisks, are clinically more useful than RMI and ROMA to select patients with adnexal masses for specialized oncology care.
Lingua originaleEnglish
pagine (da-a)5082-5090
Numero di pagine9
RivistaClinical Cancer Research
Volume23
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Adnexal Diseases
  • Aged
  • Biomarkers, Tumor
  • Cancer Research
  • Diagnosis, Differential
  • Female
  • Humans
  • Medical Oncology
  • Middle Aged
  • Oncology
  • Ovarian Neoplasms
  • Patient Selection
  • Risk Assessment
  • Ultrasonography

Fingerprint Entra nei temi di ricerca di 'Clinical utility of risk modelsto refer patients with adnexal masses to specialized oncology care: Multicenter external validation using decision curve analysis'. Insieme formano una fingerprint unica.

Cita questo